Tirzepatide vs AHK-Cu
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
TirzepatideSkin & CosmeticAnti-Aging & Longevity
AHK-Cu- Summary
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
- Half-Life
- ~5 days
- Hours (topical, variable by formulation)
- Admin Route
- SubQ
- Topical, Scalp application, Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- 0.01–0.1% concentration
- Frequency
- Once weekly, subcutaneous
- Once or twice daily
- Key Benefits
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Stimulates hair follicle growth and reduces shedding
- Increases dermal papilla cell proliferation
- Promotes wound healing and skin regeneration
- Antioxidant protection via superoxide dismutase activation
- Improves skin elasticity and firmness
- Supports collagen and elastin production
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Generally well-tolerated topically
- Mild scalp irritation or redness in sensitive individuals
- Possible temporary hair shedding phase at treatment initiation
- Copper accumulation with excessive systemic use (rare)
- Stacks With
- —
- —